Ganga Pharmaceuticals Limited

CIN: L99999MH1989PLC053392

Regd. Office: Gangatat, Dhanvantri Marg, Gopcharpada, Virar (E), Palghar - 401305 Phone: 9834613142 | Website: www.ayurvedganga.com | Email: ayurvedganga@gmail.com

May 16, 2024

To The Department of Corporate Services **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai-400001

Dear Sir,

Scrip Code: 539680

Sub.: Statement of Deviation or Variation pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

Pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this is to inform you that there is no deviation or variation in the utilization of funds raised by the Company through preferential Issue of Equity shares and Convertible Warrants on January 19, 2024 (Allotment Date). The detailed Statement of Deviation or Variation for the half and financial year ended March 31, 2024 is annexed herewith as "Annexure A".

Please acknowledge and take the same on your records.

Thanking You,

Yours faithfully,

For Ganga Pharmaceuticals Limited

Bharat Sharma Managing Director DIN: 00077026

Email ID: bharat.sharma@gangapharma.in.

Ganga Pharmaceuticals Limited

CIN: L99999MH1989PLC053392

Regd. Office: Gangatat, Dhanvantri Marg, Gopcharpada, Virar (E), Palghar - 401305 Phone: 9834613142 | Website: www.ayurvedganga.com | Email: ayurvedganga@gmail.com

Annexure A

| Statement of Deviation / Var | iation | in utilizat | tion of Fund | s raised | | Aine | xure A |
|--|-----------|--|---|-----------------------|------------|--------------------------------------|------------|
| Name of listed entity | | | Ganga Pharmaceuticals Limited | | | | |
| Mode of Fund Raising | | | Preferential Shares | Issues of Convertible | e Warrants | and | Equit |
| Date of Raising Funds | | | January 19, 2024 (Convertible Warrants & Equity Shares) | | | | |
| Amount Raised | | | Rs. 1,70,62,500 as follow:- | | | | |
| | | | • Against Convertible Warrants Rs. 62,12,500/- | | | | |
| | | | • Against Equity Shares Rs. 1,08,50,000/- | | | | |
| Report filed for Quarter ended Monitoring Agency | | | March 31, 2024 Not Applicable | | | | |
| Monitoring Agency Name, if applicable | | | Not Applicable Not Applicable | | | | |
| Is there a Deviation / Variation in use of | | | No No | | | | |
| funds raised | | | 140 | | | | |
| If yes, whether the same is pursuant to change | | | Not Applicable | | | | |
| in terms of a contract or obje approved by the shareholders | | | 11 | | | | |
| If Yes, Date of shareholder Approval | | | Not Applicable | | | | |
| Explanation for the Deviation / Variation | | | Not Applicable | | | | |
| Comments of the Audit Committee after review | | | No Comments | | | | |
| Comments of the auditors, if a | | | No Comme | | | | |
| Objects for which funds have | been ra | | | | | | |
| Original Object | Sr. No | Particulars | | Amount Upto (Rs | · 1 | Tentat Time Fr for utilizat | ame |
| | 1 | Funding capital expenditure requirements for expansion of existing manufacturing facilities including acquisition of Plant & Machinery | | 1,20,00,000 | | 18 mor | nths |
| | 2 | Augment working capital needs of the Company | | 2,00,00,000 | | 18 mor | nths |
| | 3 | For general corporate purposes | | 1,00,00,000 | | 18 mor | nths |
| Modified Object, if any | Not A | Applicable | : | | • | | |
| Original Allocation | Sr. No | Par | ticulars | Amount Upto (Rs. | | Tentat FimeFr for utilizat | ame ion |
| | 1 | manufactu facilities | ents for of existing uring including of Plant & | 48,75,000 | | 18 mor | nths |
| | 2 | Augment working capital needs of the Company | | 81,25,000 | | 18 mor | nths |

Ganga Pharmaceuticals Limited

CIN: L99999MH1989PLC053392

Regd. Office: Gangatat, Dhanvantri Marg, Gopcharpada, Virar (E), Palghar - 401305 Phone: 9834613142 | Website: www.ayurvedganga.com | Email: ayurvedganga@gmail.com

| | 3 | For general corporate purposes | 40,62,500 | 18 months | | | | |
|--|--|--|-------------------------------|-----------|--|--|--|--|
| Modified Object, if any | Not Applicable | | | | | | | |
| Funds Utilized | Sr. No | Particulars Amount Upto (Rs.) | | | | | | |
| | 1 | Funding capital expenditure requirements for expansion of existing manufacturing facilities including acquisition of Plant & Machinery | NIL | | | | | |
| | 2 | Augment working capital needs of the Company and its Subsidiaries | 56,60,782 | 56,60,782 | | | | |
| | 3 | For general corporate purposes | 38,64,592 | | | | | |
| Amount of Deviation/Variation for the quarter according to applicable object | No Do | eviation during the qua | arter ended on March 31, 2024 | | | | | |
| Remarks if any | Amount against original object and original allocation has been taken in proportionate to the amount subscribed and received as issue involved the share warrants on which 25% of amount was received. There is unutilized amount of Rs 75,37,126/- as on March 31, 2024. Out of this, Rs 75,00,000/-is F.D. and Rs. 37,126/-lying in the CC Bank account of the Company. | | | | | | | |

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund-raising document i.e., prospectus, letter of offer, etc.

Yours faithfully,

For Ganga Pharmaceuticals Limited

Bharat Sharma Managing Director DIN: 00077026

Email ID: bharat.sharma@gangapharma.in